About this trial
Nutrition is very important to keep blood sugar levels balanced. If blood sugar levels are too high, it can lead to diseases such as cardiovascular disease and type 2 diabetes (T2DM). Therefore, adjusting what one eats, also called a diet or nutritional intervention, can help prevent these diseases. However, not everyone responds the same to a diet. In about 30% of people, a diet does not work as hoped. This can be due to various reasons, such as a person's metabolism, genetic predisposition, the composition of the food one eats, or the bacteria in the intestines. Everyday things like sleep, stress, and movement also play a role. The investigators used a computer model to classify people with overweight and obesity into groups based on these factors. The investigators call such a group a 'Metabolic Phenotype', or in short 'Metabotype'. Based on the Metabotype, a personalised diet was developed (personalised nutrition intervention) that may better suit each person's unique situation.
The investigators hypothesize that a precision nutrition intervention, tailored to Metabotypes identified through unsupervised clustering (using the aforementioned computer model) of predefined, accurate features related to cardiometabolic health-specifically, tissue-specific glucose and lipid metabolism and detailed body composition-will enhance blood glucose homeostasis, reduce cardiometabolic risk, and improve adherence to the intervention and mental well-being, compared to population-based dietary guidelines. The present project will contribute to targeted and efficient precision-based dietary strategies for individuals at increased risk of T2DM.
Eligibility criteria
Qualifiers
Men and women with a BMI ≥25 to <40 kg/m2
Classification possible to one of the investigational metabolic phenotypes according to the classification algorithm.
Weight stability for at least 3 months (+/- 3 kg)
Disqualifiers
(Pre-)diagnosis of type 1 or type 2 diabetes mellitus (i.e., FPG ≥ 7,0 mmol/L) and HbA1c ≥ 6,5% (48 mmol/mol)
Renal or hepatic malfunctioning (pre-diagnosis or determined based on ALAT and creatinine values)
Food allergies, intolerances (including gluten/lactose intolerance) and/or eating disorders interfering with the study
Cardiovascular diseases (e.g., heart failure) or cancer (e.g., noninvasive skin cancer allowed)
Trial design
Treatments tested in this trial
- Optimal Metabotype-specific diet
- Sub-optimal diet
Treatment groups
Sponsors and collaborators
Maastricht University Medical Center
Lead sponsor
Wageningen University and Research
Collaborator
Health Holland
Collaborator
TKI Agri & Food
Collaborator
Nestle Health Science
Collaborator
Beneo GmbH
Collaborator
BARILLA G. e R. Fratelli S.p.A., Parma, Italy
Collaborator